MORRISVILLE, N.C., Dec. 5, 2017 /PRNewswire/ -- Magstim, a pioneer in the field of Transcranial Magnetic Stimulation (TMS), announces the release of Horizon™ TMS Therapy, a new technology platform for the treatment of Major Depressive Disorder (MDD) in adults who have failed to experience satisfactory improvement from prior antidepressant medication.
HORIZON™ TMS Therapy is a proven, safe and cost-effective treatment for MDD. TMS is non-invasive, non-systemic and has very few side effects. HORIZON™ TMS Therapy uses a focused electromagnetic coil, to rapidly pulse a magnetic field to the targeted area of the brain.
TMS is performed in a doctor's office or clinic with the patient seated in a comfortable chair while a "coil" is placed against the head. A series of repetitive, brief and highly-focused magnetic pulses are emitted to stimulate brain cells and, in depressed patients, restore brain activity to normal levels. Treatment sessions last less than 40 minutes and are typically performed five days per week, over a four to six-week period.
The new Horizon platform features a proprietary energy recovery system that delivers consistent stimulation with operational ease and reduced maintenance. Nearly two-thirds of those who have been treated by Magstim's TMS therapy report significant improvement in the way they feel.1
As one patient has stated, "I encourage anyone who suffers with depression that hasn't been successfully treated with medication to try this treatment with the goal of relief or even remission from depression. In the span of six weeks, I went from a suicidal, nearly bed-ridden, shell of a person to a happy, energetic and hopeful woman."
Magstim's technology carries the CE Mark, and has been cleared by the Food and Drug Administration (FDA) as "an effective therapy for adults with MDD who have failed to experience improvement from prior antidepressant medication in the current episode." TMS is covered by most health insurance providers in the USA, including Medicare.
Mark George, MD, a prominent researcher and clinical pioneer in the TMS field, commented, "I have used Magstim systems in research for over 20 years and am thrilled that Magstim is making advances in clinical use."
Lothar Krinke, Ph.D, Magstim Group CEO, says, "Horizon is Magstim's next generation technology platform for TMS applications. As we build on our proven record in research and continued expansion in the clinical market, we are confident that Horizon will form the basis for additional innovations that bring new hope to the millions who have been living with depression."
1. Euba, R., et.al., "Treatment-resistant depression: experience of the first repetitive transcranial magnetic stimulation clinic in the UK," Future Neurology, May 2015, Vol. 10, pp. 211-215.
About Magstim, The Brains Behind Transcranial Magnetic Stimulation (TMS)
The Magstim Company, Ltd., based in Whitland, Wales, with US headquarters in Morrisville, North Carolina, conceived transcranial magnetic stimulation (TMS) as a valuable research tool and nurtured its coming of age as a revolutionary treatment for nerve and brain disorders such as major depressive disorder (MDD). Magstim now manufactures and supplies a wide range of products for research and clinical applications. Magstim systems are used by researchers and clinicians in partnerships with leading medical and research companies globally and are cited in over 79% of TMS research conducted worldwide. The company is committed to technology innovation, medical education, and delivering flexible options to its customers.
For further information: